← Eichor
Study identifier: NCT06188065 Synced from ClinicalTrials.gov · July 28, 2026
● Recruiting

Eosinopenia in Severe COPD Exacerbation

Condition: Chronic Obstructive Pulmonary Disease  ·  Sponsor: Northumbria Healthcare NHS Foundation Trust

PhaseN/A
Planned participants200
Who can joinAll sexes, 35 Years to no upper limit
Healthy volunteersNo

About this study

The goals of this observational study are to identify factors independently associated with admission eosinopenia in patients with a severe exacerbation of chronic obstructive pulmonary disease (COPD) and to determine when blood eosinophil count (BEC) will recover to baseline stable state in patients who are admitted to hospital with a severe exacerbation of COPD and associated eosinopenia. The main aims of the study are to: 1. Identify demographic, physiological and clinical factors independently associated with admission eosinopenia in patients with a severe exacerbation of COPD 2. Assess the time to recovery from eosinopenia to stable BEC following a severe exacerbation of COPD

This description comes directly from the study's public registry record.

Talk to the study team

Stephen Bourke, MBChB, PhD  ·  0191 293 4351  ·  stephen.bourke@nhct.nhs.uk

Peter Ireland, MBBS  ·  peter.ireland@northumbria-healthcare.nhs.uk

Always discuss trial participation with your own doctor first.

Locations (1)

Northumbria Healthcare NHS Foundation TrustNorth Shields, United KingdomRecruiting

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT06188065